Tracks biomarkers in people with leukemia or follicular lymphoma
Observes blood and marrow samples from people with leukemia or follicular lymphoma.
Key facts
- Who runs it
- Tempus AI
- Where
- Bethesda, Charlotte, Cincinnati, Columbus, Fargo, Iowa City, Maumee, Reno, Rochester, Sioux Falls, St Louis, and York, United StatesSee the 13 sites
- Trial code
- Registry title
- A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Status
- Recruiting
- People taking part
- 550 people, planned
- Started
- 27 Jan 2026
- Expected to end
- Nov 2035
- Type of study
- Observational, 2 groups
- Treatments tested
- None - Observational Study
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with acute myeloid leukaemia (AML) or follicular lymphoma. They give blood and leftover tissue or bone marrow samples during routine care. It is an observation study with no study treatment.
- Age
- No age limit is given. The record lists 0 Years as the minimum age.
- Sex
- All sexes can join.
- Disease stage
- AML: a documented diagnosis, secondary AML is allowed. Follicular lymphoma: confirmed under the microscope, in one of four groups: newly diagnosed and watched, newly diagnosed high risk, relapsed or refractory high risk with progression within 24 months of first treatment, or transformed.
- Earlier treatment
- AML: no earlier standard treatment for AML. Newly diagnosed follicular lymphoma groups: no earlier treatment for follicular lymphoma. Relapsed group: progression within 24 months of first treatment, before second treatment.
Main reasons for not taking part
- Not willing or able to follow the study procedures
- AML: any earlier standard treatment for AML
- Watched newly diagnosed follicular lymphoma: earlier treatment, high-risk disease, or surgery with no evidence of disease
- High-risk newly diagnosed follicular lymphoma: planned active observation or earlier treatment
The registry criteria, word for word
Show all 19 criteriaShow less
Other criteria
- All Cohorts Inclusion Criteria:
- Willing and able to participate in the research and provide biospecimens
- Willing and able to provide informed consent; Cohort 001 Inclusion:
- Have documented diagnosis of AML according to the World Health Organization (WHO) classification
- Secondary AML is allowed; Cohort 002 Inclusion:
- Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)
- Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)
- 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation
- 002B (Newly Diagnosed, High Risk): Intended for first line treatment
- 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)
- 002C (Relapsed / Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment
- 002D (Transformed FL): Pathologically confirmed transformation; All Cohorts Exclusion Criteria:
- Not willing or able to adhere with the study procedures; Cohort 001:
- Have received any prior therapy intended for standard of care (SoC) treatment of AML; Cohort 002:
- 002A: Received prior treatment for follicular lymphoma
- 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN
- 002A: Resected patients with NED
- 002B: Intended for active observation
- 002B: Received prior treatment for follicular lymphoma
Where in United States
- The Center for Cancer and Blood DisordersBethesda, United StatesContact: Kosunique JenkinsTaking people
- Novant Health Weisiger Cancer InstituteCharlotte, United StatesContact: Gait JordanTaking people
- University of CincinnatiCincinnati, United StatesContact: Bethany FuhrmanTaking people
- OhioHealth Research InstituteColumbus, United StatesContact: Kevin MillerTaking people
- Sanford FargoFargo, United StatesContact: Jamie SchmidtTaking people
- University of Iowa Hospital and ClinicsIowa City, United StatesContact: Herman BernabeTaking people
- Taylor Cancer Research CenterMaumee, United StatesContact: Jennifer MartinezTaking people
- Cancer Care Specialists of RenoReno, United StatesContact: Layla QuinonezTaking people
- University of RochesterRochester, United StatesContact: Donald BurnsTaking people
- Avera Cancer InstitueSioux Falls, United StatesTaking people
- Sanford Sioux FallsSioux Falls, United StatesContact: Michaela MelbergTaking people
- Washington University in St. LouisSt Louis, United StatesContact: Emily VukadinovicTaking people
- Cancer Care Associates of YorkYork, United StatesContact: Clarissa VegaTaking people
About the trial
What the trial wants to find out
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
The 2 groups in the trial
- Cohort 001: Newly Diagnosed Acute Myeloid Leukemia (AML)
Newly diagnosed patients with a primary or secondary diagnosis of Acute Myeloid Leukemia (AML)
Treatment: None - Observational Study
- Cohort 002: Folicular Lymphoma
Cohort 002 contains four subgroups of Follicular Lymphoma (FL): A: Newly Diagnosed FL on Active Observation; B: Newly Diagnosed High Risk FL; C: Relapsed / Refractory High Risk POD24 FL; D: Transformed FL
Treatment: None - Observational Study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Plain-language title
- Tracks biomarkers in people with leukemia or follicular lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 October 2026